Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States

Journal of Medical Economics ◽

10.1080/13696998.2018.1443111 ◽

2018 ◽

Vol 21 (6) ◽

pp. 577-586 ◽

Author(s):

Zheng-Yi Zhou ◽

Alex Mutebi ◽

Simeng Han ◽

Arielle G. Bensimon ◽

Marie Louise Ricculli ◽

...

Keyword(s):

United States ◽

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

The United States ◽

Small Cell Lung ◽

Anaplastic Lymphoma

Download Full-text

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1886928 ◽

2021 ◽

pp. 1-13

Author(s):

Anthony Yu ◽

Eva Huang ◽

Momoka Abe ◽

Kang An ◽

Sun-Kyeong Park ◽

...

Keyword(s):

United States ◽

Lung Cancer ◽

Systematic Review ◽

Targeted Therapy ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

The United States ◽

Small Cell Lung

Download Full-text

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Cancer Management and Research ◽

10.2147/cmar.s223441 ◽

2019 ◽

Vol Volume 11 ◽

pp. 9195-9202 ◽

Author(s):

Maobai Liu ◽

Longfeng Zhang ◽

Qishu Huang ◽

Na Li ◽

Bin Zheng ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis

Download Full-text

Cost Effectiveness of Crizotinib for Anaplastic Lymphoma Kinase–Positive, Non–Small-Cell Lung Cancer: Who Is Going to Blink at the Cost?

Journal of Clinical Oncology ◽

10.1200/jco.2013.54.6002 ◽

2014 ◽

Vol 32 (10) ◽

pp. 983-985 ◽

Author(s):

Ronan J. Kelly ◽

Bruce E. Hillner ◽

Thomas J. Smith

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Download Full-text

Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer

Clinical Drug Investigation ◽

10.1007/s40261-019-00880-8 ◽

2019 ◽

Vol 40 (2) ◽

pp. 183-189 ◽

Author(s):

Hongchao Li ◽

Lei Lai ◽

Bin Wu

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Anaplastic Lymphoma

Download Full-text

Cost-Effectiveness Of Ceritinib In Previously Treated Patients With Crizotinib In Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small Cell Lung Cancer In Canada

Value in Health ◽

10.1016/j.jval.2015.09.1199 ◽

2015 ◽

Vol 18 (7) ◽

pp. A462 ◽

Author(s):

Z Zhou ◽

M Hurry ◽

J Zhang ◽

L Fan ◽

C Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Previously Treated Patients ◽

Previously Treated

Download Full-text

Cost-Effectiveness of Crizotinib, Ceritinib, and Alectinib as First-Line Treatments for Anaplastic Lymphoma Kinase-Positive (ALK+) Metastatic Non-Small Cell Lung Cancer

Value in Health ◽

10.1016/j.jval.2018.04.208 ◽

2018 ◽

Vol 21 ◽

pp. S32-S33

Author(s):

S Xuan ◽

J Ma

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Anaplastic Lymphoma

Download Full-text

Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada

Journal of Medical Economics ◽

10.1080/13696998.2016.1187151 ◽

2016 ◽

Vol 19 (10) ◽

pp. 936-944 ◽

Author(s):

Manjusha Hurry ◽

Zheng-Yi Zhou ◽

Jie Zhang ◽

Chenxue Zhang ◽

Liangyi Fan ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Previously Treated

Download Full-text

PCN140 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VS CRIZOTINIB IN FIRST LINE ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN PORTUGAL

Value in Health ◽

10.1016/j.jval.2018.09.223 ◽

2018 ◽

Vol 21 ◽

pp. S38

Author(s):

V. Soares ◽

P. Orfanos ◽

C. Pereira

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis

Download Full-text

PCN54 COST-EFFECTIVENESS ANALYSIS OF CERITINIB IN PATIENTS PREVIOUSLY TREATED WITH CRIZOTINIB AND CHEMOTHERAPY IN ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK+) NON-SMALL CELL LUNG CANCER IN UNITED STATES

Value in Health ◽

10.1016/j.jval.2020.04.1558 ◽

2020 ◽

Vol 23 ◽

pp. S32

Author(s):

Y. Zhang ◽

Y. Shao ◽

L. Shi

Keyword(s):

United States ◽

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis ◽

Previously Treated

Download Full-text

Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer

PharmacoEconomics ◽

10.1007/s40273-018-0625-6 ◽

2018 ◽

Vol 36 (4) ◽

pp. 495-504 ◽

Author(s):

Josh J. Carlson ◽

Kangho Suh ◽

Panos Orfanos ◽

William Wong

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Anaplastic Lymphoma

Download Full-text